skip to content

Market News

SKP says SKP-2076 to be partnered with Mundipharma

23 December 2015 07:40

Skyepharma has entered into a feasibility and option agreement with Mundipharma Laboratories GmbH, which is expected to lead to the Mundipharma network of independent associated companies ("Mundipharma") being the global development and commercialisation partner for SKP-2076, Skyepharma's novel triple ICS/LABA/LAMA1 fixed dose combination product in a pressurised Metered Dose Inhaler (pMDI).

Story provided by StockMarketWire.com

Related Company: SKP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.